Table 1.

Currently available prognostic scoring systems in MDS

System	Blood			Marrow		Patient			Comments
	Hgb	PLTs	ANC	Blasts	Cyto	Age	Txn	PS
IPSS	+	+	+	+	+	+			Has been revised now (2012) using the same prognostic parameters (number and depth or cytopenias, marrow blast percentage [more granular] and karyotype), was able to reclassify nearly 25% of lower-risk MDS patients into a higher-risk category
WPSS				+	+		+		Time dependent which is useful over the course of patient's disease
MDS LR		+	+	+	+	+	+		May be applied specifically to lower-risk disease with more variables
MDAPSS		+	+	+	+	+	+	+	Contains more clinical variables, especially age and transfusion burden, which could upstage a patient
FPSS	+			+		+			Higher-risk disease and includes azacytidine-treated patients, likely is not useful in lower-risk patients, even for upstaging
IPSS-R	+	+	+	+	+	+			Used most commonly at diagnosis and for clinical trial eligibility, limitations discussed in text

The prognostic scoring systems are listed in order of publication with annotations on the variables included and comments on their use in lower risk disease.

Cyto, cytogenetics; FPSS, French Prognostic Scoring System; MDAPSS, MD Anderson Prognostic Scoring System; MDS LR, scoring system for patients with lower-risk MDS; PS, performance status; Txn, transfusions; WPSS, WHO Classification-Based Prognostic Scoring System.